Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.43 |
| ▸ | UBE2M | P61081 | 8/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 8/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799743 | 0.92 | LMNA (0.44) | LMNATRPV1UBE2MDCUN1D1THRB | |
| SCHEMBL2797154 | 0.91 | LMNA (0.43) | LMNATRPV1UBE2MDCUN1D1THRB | |
| SCHEMBL5041805 | 0.91 | LMNA (0.47) | LMNATRPV1UBE2MDCUN1D1THRB | |
| SCHEMBL2796342 | 0.91 | LMNA (0.43) | LMNATRPV1UBE2MDCUN1D1THRB | |
| SCHEMBL12000199 | 0.87 | UBE2M (0.42) | LMNAUBE2MDCUN1D1THRB | |
| SCHEMBL2800186 | 0.86 | UBE2M (0.42) | LMNAUBE2MDCUN1D1THRB | |
| SCHEMBL2797187 | 0.86 | UBE2M (0.41) | LMNAUBE2MDCUN1D1THRB | |
| SCHEMBL2799504 | 0.86 | UBE2M (0.41) | LMNAUBE2MDCUN1D1THRB | |
| SCHEMBL2799027 | 0.86 | UBE2M (0.41) | LMNAUBE2MDCUN1D1THRB | |
| SCHEMBL2800234 | 0.86 | LMNA (0.44) | LMNAUBE2MDCUN1D1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | LMNA 4185/4885TRPV1 2158/4885UBE2M 2433/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | LMNA 2947/4885TRPV1 1745/4885UBE2M 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.